

## AMENDMENTS TO THE CLAIMS

1. – 18. (previously cancelled)

19. (currently amended) A method for the treatment of male erectile dysfunction which comprises administering to a male in need thereof a pharmacologically effective amount of a composition comprising an  $\alpha$ -adrenergic blocker and a prostaglandin in a buffer, **wherein the buffer comprises a substrate for nitric oxide synthetase.**

20. (original) The method of claim 19 wherein the  $\alpha$ -adrenergic blocker is phentolamine mesylate, or any pharmaceutically acceptable salt thereof.

21. (cancelled)

22. (original) The method of claim 19 wherein the prostaglandin is alprostadil.

23. (original ) The method of claim 19 wherein the buffer comprises L-arginine and, optionally, a pharmaceutically acceptable excipient or carrier.

24. (original) The method of claim 23 wherein the buffer comprises glycine having a pH range of from about 3 to about 5.

25. (original) The method of claim 19 wherein the buffer comprises a mixture of arginine and glycine having a pH range of from about 3 to about 5.

26. (original) The method of claim 19 wherein the buffer comprises glycine and L-arginine in a weight ratio of about 1:20.

27. (original) The method of claim 25 wherein the buffer further comprises benzyl alcohol and mannitol and has a pH range of from about 3 to about 5.

28. (original) The method of claim 19 wherein the weight ratio of phentolamine mesylate: alprostadil is about 0.5:0.005 to about 5: 0.20.

29. (original) The method of claim 19 wherein the weight ratio of phentolamine mesylate: alprostadil is about 1:0.01.

30. (original) The method of claim 19 wherein the dosage of phentolamine mesylate and alprostadil are in the range of about 0-40  $\mu$ g/ml alprostadil-and about 0-10 mg/ml phentolamine.

31. (original) The method of claim 19 wherein the dosage of phentolamine mesylate and alprostadil are in the range of about 1.25-5 mg/ml phentolamine and about 5-20  $\mu$ g/ml alprostadil.

32. (original) The method of claim 19 wherein the dosage of phentolamine mesylate and alprostadil are about 1 mg/ml phentolamine and about 0.01 mg/ml alprostadil.

33. (original) The method of claim 30, 31, or 32 wherein the vasoactive agents are present in a total volume of 0.5 ml.

34. (original) The method of claim 19 wherein the dosage of alprostadil is about 5  $\mu$ g/ml in a total volume of 0.5 ml.

35. (original) The method of claim 19 wherein the dosage of phentolamine is about 1.25 mg/ml in a total volume of 0.5 ml.

36. (original) The method of claim 19 wherein the pH range of the buffer is from about 3 to about 7.

37. – 46. (previously cancelled)